Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01667510
Other study ID # Lyc-2012-01
Secondary ID
Status Completed
Phase N/A
First received August 12, 2012
Last updated December 21, 2017
Start date August 2012
Est. completion date August 2013

Study information

Verified date August 2012
Source LycoRed Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The hypothesis of the study is that supplementation with Cardio Mato (a Tomato Extracted Lycopene)for 12 weeks will decrease the blood pressure of subjects with prehypertension compared to Placebo.


Description:

Blood-pressure reading of 140/90 mmHg (systolic/diastolic pressure) are typically regarded as having high blood pressure as defined in the most recent guidelines. From a physiological perspective, the regulation of blood pressure is a complicated process involving different biological systems and a number of feedback systems, including the nervous system, hormones, control of body fluid and regulators within the vessels themselves. In 90-95% of patients with high blood pressure the cause is unknown, whereas the remaining 5-10% may have secondary hypertension related to congenital heart defects, certain cancers or kidney abnormalities. Prehypertension [systolic blood pressure (SBP) 120-139 mm Hg, diastolic blood pressure (DBP) 80-89 mm Hg] is considered a precursor of hypertension and has been associated with an increased risk of up to 3.5 times in cardiovascular morbidity and mortality later in life.

According the report of the Joint National Committee on High Blood Pressure (JNC 7) and other international guidelines, weight control, reduced intake of salt and reduced alcohol consumption, as well as increase of potassium are recommend nutritional approaches to prevent and treat hypertension. In observational studies significant inverse association between high blood pressure and vegetarian diet rich in fibers, magnesium, potassium, calcium and protein have been reported. In addition various studies demonstrated the ability of antioxidant vitamins of natural origin to improve vascular function.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date August 2013
Est. primary completion date June 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Male and female subjects aged 18-65, both inclusive

2. Established Pre-hypertension defined as: Mean baseline SBP 130-139 mmHg and DBP of 89 mmHg or lower or SBP of 139 mmHg or lower and DBP of 85- 89 mmHg, at screening, eligibility and randomization visits

3. Subjects that did not receive any antihypertensive treatment in the past o present

4. Subjects that are willing to sign an informed consent form prior to joining the study

Exclusion Criteria:

1. Subjects with Mean baseline SBP higher than 120 and lower than 130 mmHg

2. Subjects with Mean baseline DBP higher than 80 and lower than 85 mmHg

3. Subjects who are treated for blood pressure reduction (any treatment)

4. Subjects under treatment with other chronic medications (e.g. statins, NSAID etc.)

5. Subjects that use antioxidant agents or vitamins within 4 weeks prior to inclusion into the study

6. Subjects that will not be able to follow the study dietary proscriptions from the screening visit through the final visit

7. Subjects following any special diet including, but not limited to liquid, high or low protein, raw food, vegetarian or vegan, etc

8. Subjects with known allergy to tomatoes, carotenoids, or vitamin E

9. Subjects diagnosed with Diabetes Mellitus

10. Subjects suffering from obesity

11. Subjects Suffering from a clinically significant dyslipidaemia

12. Subjects suffering from cardiac disease; e.g. suffering from cardiac angina, subjects that were diagnosed with and MI, subjects that needed PTCA or CABG. Subjects diagnosed with LVH, CHF or valvular heart disease

13. Subjects diagnosed with PVD

14. Subjects who were diagnosed with Cerebrovascular disease, s/p CVA, TIA

15. Subjects who suffer from any kind of kidney disease

16. Subjects who suffer from chronic liver disease; defined as elevated AST and ALT at least by 2 times of the normal range

17. Subject with history or current use of illegal or "recreational" drugs

18. Subjects with a history of GI disease or surgery within 6 months prior to study inclusion

19. Subjects with a history of malignancy in the past 5 years

20. Subjects with a history of autoimmune disease

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Cardio Mato
Soft gel capsule for oral use
Placebo
Soft gel capsule without test material

Locations

Country Name City State
Israel Maccabi Health care, outpatient clinic Holon

Sponsors (2)

Lead Sponsor Collaborator
LycoRed Ltd. Maccabi Healthcare Services, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of adverse events recorded during the supplementation period, lycopene compared to placebo AE epizoda 12 weeks
Primary The effect Lyc-O-Mato on the blood pressure of pre-hypertensive otherwise healthy subjects compared to the placebo group following 12 weeks of treatment Change in blood pressure from baseline to 12 weeks in mmHG 12 weeks
Secondary The effect Cardio Mato on the blood pressure of Pre-hypertensive otherwise healthy subjects compared to the placebo group following 4 and 8 weeks of treatment Change in blood pressure from baseline to 4 and 8 weeks in mmHG 4-8 weeks
Secondary The correlation between B.P changes in the Cardio Mato or placebo treatment arms during the study with serum lycopene phytofluene, and phytoene levels B.P change 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Completed NCT02551640 - Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients N/A
Recruiting NCT01483430 - Effect of Ginseol Kg1 on Blood Pressure Lowering Phase 3
Terminated NCT01295216 - Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings N/A
Completed NCT01637909 - Korean Life-Style Modification Effects on Blood Pressure N/A
Unknown status NCT01308983 - Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension Phase 4
Active, not recruiting NCT03596099 - Rice Vinegar as an Intervention to Lower Blood Pressure in Adults With Prehypertension and 10-year CVD Risk <10% N/A
Completed NCT04326686 - Measuring Individual Responses to a Wholegrains and Nuts Intervention to Reduce Blood Pressure in Prehypertension N/A
Completed NCT03898518 - The Effects of a Jump Rope Exercise Program on Body Composition and Self-efficacy in Obese Adolescent Girls N/A
Terminated NCT01983462 - Vascular Dysfunction in Human Obesity Hypertension Phase 2
Completed NCT01472692 - Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure Phase 4
Completed NCT01458496 - Health Coaching to Effect Lifestyle Behaviour Change N/A
Completed NCT03266510 - Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function N/A
Completed NCT02998840 - A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure Phase 2
Completed NCT01974570 - Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects Phase 2
Completed NCT02326766 - Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects Phase 3
Completed NCT01395329 - Nebivolol and the Endothelin (ET)-1 System Phase 4
Completed NCT01331486 - Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract Phase 1
Completed NCT05274971 - Diet and Exercise on Ambulatory Blood Pressure N/A
Active, not recruiting NCT02371317 - Stress Management for High Blood Pressure N/A